Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A, Ntavatzikos A, Symeonidis D, Vallilas C, Giannakakou M, Papaxoinis G, Xynogalos S, Boukovinas I, Demiri S, Kampoli K, Oikonomopoulos G, Samantas E, Res E, Androulakis N, Vourli G, Souglakos I, Karamouzis M. Koumarianou A, et al. Among authors: papaxoinis g. Biomedicines. 2023 Apr 24;11(5):1267. doi: 10.3390/biomedicines11051267. Biomedicines. 2023. PMID: 37238938 Free PMC article.
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T, Raptis SA. Pectasides D, et al. Among authors: papaxoinis g. Gynecol Oncol. 2004 Oct;95(1):165-72. doi: 10.1016/j.ygyno.2004.06.029. Gynecol Oncol. 2004. PMID: 15385127 Clinical Trial.
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
Moutafi M, Koliou GA, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Kyrodimos E, Delides A, Giotakis E, Papadimitriou NG, Panayiotides IG, Perisanidis C, Fernandez AI, Xirou V, Poulios C, Gagari E, Yaghoobi V, Gavrielatou N, Shafi S, Aung TN, Kougioumtzopoulou A, Kouloulias V, Palialexis K, Gkolfinopoulos S, Strati A, Lianidou E, Fountzilas G, Rimm DL, Foukas PG, Psyrri A. Moutafi M, et al. Among authors: papaxoinis g. Cancer Res Commun. 2023 Aug 10;3(8):1514-1523. doi: 10.1158/2767-9764.CRC-23-0051. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37575280 Free PMC article. Clinical Trial.
Hereditary Diffuse Gastric Cancer: A 2022 Update.
Kole C, Charalampakis N, Sakellariou S, Papaxoinis G, Apostolou KG, Machairas N, Papanikolaou IS, Schizas D. Kole C, et al. Among authors: papaxoinis g. J Pers Med. 2022 Dec 8;12(12):2032. doi: 10.3390/jpm12122032. J Pers Med. 2022. PMID: 36556253 Free PMC article. Review.
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Kamposioras K, Papaxoinis G, Dawood M, Appleyard J, Collinson F, Lamarca A, Ahmad U, Hubner RA, Wright F, Pihlak R, Damyanova I, Razzaq B, Valle JW, McNamara MG, Anthoney A. Kamposioras K, et al. Among authors: papaxoinis g. Acta Oncol. 2022 May;61(5):583-590. doi: 10.1080/0284186X.2022.2053198. Epub 2022 Apr 7. Acta Oncol. 2022. PMID: 35392758
88 results